Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule

被引:99
作者
Rosenthal, Adam N. [1 ,2 ]
Fraser, Lindsay [2 ]
Manchanda, Ranjit [2 ]
Badman, Philip [2 ]
Philpott, Susan [2 ]
Mozersky, Jessica [2 ]
Hadwin, Richard [2 ]
Cafferty, Fay H.
Benjamin, Elizabeth
Singh, Naveena [3 ]
Evans, D. Gareth [4 ]
Eccles, Diana M. [5 ]
Skates, Steven J. [6 ,7 ]
Mackay, James [2 ]
Menon, Usha [2 ]
Jacobs, Ian J. [2 ]
机构
[1] Queen Mary Univ London, Ctr Mol Oncol, Barts & London Sch Med & Dent, John Vane Sci Ctr,Barts Canc Inst, London EC1M 6BQ, England
[2] UCL, London WC1E 6BT, England
[3] Barts & London Natl Hlth Serv Trust, London, England
[4] St Marys Hosp Manchester, Manchester, Lancs, England
[5] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Harvard Univ, Sch Med, Boston, MA USA
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
REDUCING SALPINGO-OOPHORECTOMY; BRCA2; MUTATIONS; LYNCH SYNDROME; HIGH-RISK; WOMEN; BREAST; POPULATION; PENETRANCE; CARCINOMA; CARRIERS;
D O I
10.1200/JCO.2011.39.7638
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention. Patients and Methods Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated >= 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries. Results Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have >= stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC. Conclusion These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection. J Clin Oncol 31:49-57. (c) 2012 by American Society of Clinical Oncology
引用
收藏
页码:49 / 57
页数:9
相关论文
共 43 条
  • [1] [Anonymous], CLIN PRACT GUID ONC
  • [2] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [3] Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
    Barrow, E.
    Robinson, L.
    Alduaij, W.
    Shenton, A.
    Clancy, T.
    Lalloo, F.
    Hill, J.
    Evans, D. G.
    [J]. CLINICAL GENETICS, 2009, 75 (02) : 141 - 149
  • [4] EXTRAOVARIAN PERITONEAL SEROUS PAPILLARY CARCINOMA - A CASE-CONTROL RETROSPECTIVE COMPARISON TO PAPILLARY ADENOCARCINOMA OF THE OVARY
    BLOSS, JD
    LIAO, SY
    BULLER, RE
    MANETTA, A
    BERMAN, ML
    MCMEEKIN, S
    BLOSS, LP
    DISAIA, PJ
    [J]. GYNECOLOGIC ONCOLOGY, 1993, 50 (03) : 347 - 351
  • [5] The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection
    Brown, Patrick O.
    Palmer, Chana
    [J]. PLOS MEDICINE, 2009, 6 (07)
  • [6] Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
    Buys, Saundra S.
    Partridge, Edward
    Black, Amanda
    Johnson, Christine C.
    Lamerato, Lois
    Isaacs, Claudine
    Reding, Douglas J.
    Greenlee, Robert T.
    Yokochi, Lance A.
    Kessel, Bruce
    Crawford, E. David
    Church, Timothy R.
    Andriole, Gerald L.
    Weissfeld, Joel L.
    Fouad, Mona N.
    Chia, David
    O'Brien, Barbara
    Ragard, Lawrence R.
    Clapp, Jonathan D.
    Rathmell, Joshua M.
    Riley, Thomas L.
    Hartge, Patricia
    Pinsky, Paul F.
    Zhu, Claire S.
    Izmirlian, Grant
    Kramer, Barnett S.
    Miller, Anthony B.
    Xu, Jian-Lun
    Prorok, Philip C.
    Gohagan, John K.
    Berg, Christine D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2295 - 2303
  • [7] Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome
    Cederquist, K
    Emanuelsson, M
    Wiklund, F
    Golovleva, I
    Palmqvist, R
    Grönberg, H
    [J]. CLINICAL GENETICS, 2005, 68 (06) : 533 - 541
  • [8] Characterization of BRCA1 and BRCA2 mutations in a large United States sample
    Chen, SN
    Iversen, ES
    Friebel, T
    Finkelstein, D
    Weber, BL
    Eisen, A
    Peterson, LE
    Schildkraut, JM
    Isaacs, C
    Peshkin, BN
    Corio, C
    Leondaridis, L
    Tomlinson, G
    Dutsm, D
    Kerber, R
    Amos, CI
    Strong, LC
    Berry, DA
    Euthus, DM
    Parmigiani, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 863 - 871
  • [9] Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
    Coleman, M. P.
    Forman, D.
    Bryant, H.
    Butler, J.
    Rachet, B.
    Maringe, C.
    Nur, U.
    Tracey, E.
    Coory, M.
    Hatcher, J.
    McGahan, C. E.
    Turner, D.
    Marrett, L.
    Gjerstorff, M. L.
    Johannesen, T. B.
    Adolfsson, J.
    Lambe, M.
    Lawrence, G.
    Meechan, D.
    Morris, E. J.
    Middleton, R.
    Steward, J.
    Richards, M. A.
    [J]. LANCET, 2011, 377 (9760) : 127 - 138
  • [10] Prospectively detected cancer in familial breast/ovarian cancer screening
    Dorum, A
    Heimdal, K
    Lovslett, K
    Kristensen, G
    Hansen, LJ
    Sandvei, R
    Schiefloe, A
    Hagen, B
    Himmelmann, A
    Jerve, F
    Shetelig, K
    Fjaerestad, I
    Tropé, C
    Moller, P
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1999, 78 (10) : 906 - 911